Amgen Inc. (AMGN)
| Market Cap | 146.07B |
| Revenue (ttm) | 34.13B |
| Net Income (ttm) | 5.93B |
| Shares Out | 537.71M |
| EPS (ttm) | 10.94 |
| PE Ratio | 24.83 |
| Forward PE | 13.12 |
| Dividend | $9.52 (3.50%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 2,528,645 |
| Open | 269.48 |
| Previous Close | 271.90 |
| Day's Range | 269.13 - 272.52 |
| 52-Week Range | 253.30 - 346.85 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 323.62 (+19.13%) |
| Earnings Date | May 1, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $323.62, which is an increase of 19.13% from the latest price.
News
Amgen Inc. (AMGN) RBC Capital Markets Global Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN) RBC Capital Markets Global Healthcare Conference May 21, 2025 9:00 AM ET Company Participants Justin Claeys - VP, IR Kave Niksefat - Senior Vice President of Global Marketing...
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m.
Amgen owes $406 million for monopolizing cholesterol drug market, US jury says
A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-re...
Stock Of The Day: Amgen Slips With Healthcare Sector, But Signals Point To A Reversal
The stock of Amgen Inc. AMGN is trading higher on Thursday. But along with the rest of the healthcare sector, it is still in a steep downtrend.
Amgen Inc. (AMGN) BofA Securities 2025 Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN) BofA Securities 2025 Healthcare Conference Call May 14, 2025 12:20 PM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer Justin Cla...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
European pharma stocks follow Asia peers down as Trump moves to cut prices
European drugmakers stocks fell in early trading on Monday after U.S. President Donald Trump said he would sign an executive order on reducing prescription drug and pharmaceutical prices.
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m.
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI
Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Lif...
Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as ...
Amgen: Waiting Patiently For A Real Catalyst
Amgen Inc.'s diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, bu...
Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1
Amgen reported strong Q1 results with a 9% YoY revenue increase and a 24% rise in operating EPS, but shares dipped due to risk-on market sentiment. Despite competitive pressures and softer EPS trends,...
Dogs Of The Dow Chase May's 'Safer' Buy
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding the single share price, supported by adequate free cash flow. Analyst projections suggest top Dow Dogs cou...
Committee Movers: Eaton Corp PLC, Blackstone, Amgen, EOG Resources, Chevron and Exxon Mobile
Watch as the Investment Committee breaks down the latest market movers and shakers.
Amgen Inc. (AMGN) Q1 2025 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Comm...
Amgen quarterly profit tops Wall Street view, sales up 11%
Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales increased 11% and profit margins widened.
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025.
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the...
Amgen CEO announces $1 billion in new investments
Amgen chairman and CEO Robert Bradway unpacks the company's investments on 'The Claman Countdown.'
Amgen to expand Ohio biotech manufacturing plant
Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S. capacity amid Trump administratio...
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs THOUSAND OAKS, Calif. , April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio man...